海思科与艾伯维就Nav1.8项目签署独家许可协议

美股速递
Apr 12

海思科医药集团宣布,已与艾伯维集团就其Nav1.8项目达成独家许可协议。这一合作标志着双方在创新药物研发领域迈出关键一步,有望为疼痛治疗领域带来新的突破。根据协议条款,海思科将授予艾伯维独家权益,共同推进Nav1.8靶向药物的全球开发和商业化进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10